ସୋଟୋରାସିବ

ସୋଟୋରାସିବ
Clinical data
Trade names	Lumakras, Lumykras
Synonyms	AMG 510
AHFS/Drugs.com	monograph
data	US DailyMed: Sotorasib;
Pregnancy; category	AU: B3 ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ; EU: Rx-only ;
Identifiers
	IUPAC name 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one;
Chemical and physical data
Formula	C30H30F2N6O3
Molar mass	୫୬୦.୬୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F;
	InChI InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1; Key:NXQKSXLFSAEQCZ-SFHVURJKSA-N;

ସୋଟୋରାସିବ, ବେପାର ନାମ ଲୁଟାକ୍ରାସ୍ ଏବଂ ଲୁମିକ୍ରାସ୍, ଏକ ଅଣ-ଛୋଟ-ଜୀବକୋଷ ଫୁସଫୁସ କର୍କଟ (NSCLC) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୪] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ପ୍ରଗତି ହୋଇଥିବା ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁଥିରେ କେଆରଏ‌ଏସ ଜି୧୨ସି ମ୍ୟଟେସନ ହୋଇଛି (KRAS G12C-ମ୍ୟୁଟେସନ୍) ଏବଂ ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ବିଫଳ ହୋଇଛି ।^[୪] ^[୩] ଏହା ପାଟିଦ୍ୱାରା ନିଆଯାଏ | ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, କଙ୍କାଳୀୟ ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, ଅଇ, ଥକାପଣ, ଯକୃତ ନଷ୍ଟ ଏବଂ କାଶ ହୋଇପାରେ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଇଣ୍ଟରସ୍ଟିସିଆଲ୍ ଫୁସଫୁସ ରୋଗ ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ।^[୪] ଏହା କେଆରଏଏସ ପି ଜି ୧୨ ସି (KRAS p. G12C) ମ୍ୟୁଟେସନ ଥିବା ଆର ଏ ଏସ ଜିଟିପେଜ ((RAS GTPase) ପରିବାରର ନିରୋଧୀ ଭାବରେ କାର୍ଯ୍ୟକ୍ଷମ ପରିବାରର ହୁଏ । ^[୪] ^[୬]

୨୦୨୧ ମସିହାରେ ଏବଂ ୨୦୨୨ ମସିହାରେ ୟୁରୋପରେ ସୋଟୋରାସିବକୁ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ^[୪]^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଔଷଧ ଖର୍ଚ୍ଚ ୬୯୦୦ ପାଉଣ୍ଡ ଥିଲା। ^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ଖର୍ଚ୍ଚ ପ୍ରାୟ ୧୮ ,୯୦୦ ଡଲାର ଥିଲା ।^[୮]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Lumakras". Therapeutic Goods Administration (TGA). 13 April 2022. Archived from the original on 12 April 2022. Retrieved 23 April 2022.
↑ "Summary Basis of Decision (SBD) for Lumakras". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Lumykras EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 23 April 2022. Retrieved 23 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Lumakras- sotorasib tablet, coated". DailyMed. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
↑ "FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy". U.S. Food and Drug Administration (FDA). 28 May 2021. Archived from the original on 28 May 2021. Retrieved 28 May 2021. This article incorporates text from this source, which is in the public domain.
↑ "KRAS mutant-targeting AMG 510". NCI Drug Dictionary. National Cancer Institute. 2 February 2011. Archived from the original on 10 July 2019. Retrieved 16 November 2019.
↑ "Sotorasib". SPS - Specialist Pharmacy Service. 24 September 2020. Archived from the original on 3 March 2022. Retrieved 29 October 2022.
↑ "Sotorasib". Archived from the original on 29 October 2022. Retrieved 29 October 2022.

[Lumakras_APMDS-1] ୧.୦ ^୧.୧ "Lumakras". Therapeutic Goods Administration (TGA). 13 April 2022. Archived from the original on 12 April 2022. Retrieved 23 April 2022.

[2] "Summary Basis of Decision (SBD) for Lumakras". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ "Lumykras EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 23 April 2022. Retrieved 23 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Lumakras- sotorasib tablet, coated". DailyMed. Archived from the original on 6 June 2021. Retrieved 6 June 2021.

[FDA_PR_20210528-5] "FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy". U.S. Food and Drug Administration (FDA). 28 May 2021. Archived from the original on 28 May 2021. Retrieved 28 May 2021. This article incorporates text from this source, which is in the public domain.

[6] "KRAS mutant-targeting AMG 510". NCI Drug Dictionary. National Cancer Institute. 2 February 2011. Archived from the original on 10 July 2019. Retrieved 16 November 2019.

[7] "Sotorasib". SPS - Specialist Pharmacy Service. 24 September 2020. Archived from the original on 3 March 2022. Retrieved 29 October 2022.

[8] "Sotorasib". Archived from the original on 29 October 2022. Retrieved 29 October 2022.

[୪]

[୩]

[୧]

[୨]

[୫]

[୬]

[୭]

[୮]